The price of IO Biotech Inc. (NASDAQ:IOBT) shares last traded on Wall Street rose 3.15% to $2.62.
Based on available information, 5 analysts follow IO Biotech Inc. (NASDAQ:IOBT). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $20.00 and a low of $10.00, we find $15.00. Given the previous closing price of $2.54, this indicates a potential upside of 490.55 percent. IOBT stock price is now -2.64% away from the 50-day moving average and -35.40% away from the 200-day moving average. The market capitalization of the company currently stands at $83.87M.
Among analysts, 0 rate the stock a hold while 5 rate it a buy. Brokers who have rated the stock have averaged $15.00 as their price target over the next twelve months.
A total of 11.14% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in IOBT stock. A new stake in IO Biotech Inc. shares was purchased by NEWTYN MANAGEMENT, LLC during the first quarter worth $262,000. VICTORY CAPITAL MANAGEMENT INC invested $115,000 in shares of IOBT during the first quarter. In the first quarter, PSAGOT VALUE HOLDINGS LTD. / (ISRAEL) acquired a new stake in IO Biotech Inc. valued at approximately $107,000. RENAISSANCE TECHNOLOGIES LLC acquired a new stake in IOBT for approximately $48,000. ANCORA ADVISORS, LLC purchased a new stake in IOBT valued at around $2,000 in the second quarter. In total, there are 22 active investors with 82.70% ownership of the company’s stock.
A candlestick chart of IO Biotech Inc. (NASDAQ: IOBT) showed a price of $2.4100 on Thursday morning. During the past 12 months, IO Biotech Inc. has had a low of $2.15 and a high of $9.77. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 25.00, and a quick ratio of 25.00. The fifty day moving average price for IOBT is $2.6910 and a two-hundred day moving average price translates $4.0560 for the stock.
The latest earnings results from IO Biotech Inc. (NASDAQ: IOBT) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.64, beating analysts’ expectations of -$0.68 by 0.04. This compares to -$25.18 EPS in the same period last year. The company reported revenue of $15.87 million for the quarter, compared to $7.04 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 125.29 percent.
IO Biotech Inc.(IOBT) Company Profile
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company’s lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.